Oral manifestations in patients with aplastic anemia.
OBJECTIVE
The aim of the present study was to characterize the prevalence and risks of oral complications in aplastic anemia (AA).


METHODS
Approximately 79 patients with AA (age, 37 +/- 17 years) and 66 control patients with schizophrenia (age, 33 +/- 12 years) were examined. Records were reviewed for demographic, clinical, and radiographic information. Prior medical therapy, laboratory values, disease duration, and medical treatment response were noted for patients with AA. Odds ratios (OR) and 95% CI were calculated for oral manifestations in cases and in control subjects. Univariate analysis identified important variables for logistic regression.


RESULTS
Patients with AA presented more frequently with oral petechiae (OR = 49; 95% CI, 2.9-825), gingival hyperplasia (OR = 27; 95% CI, 1.6-463.5), spontaneous gingival bleeding (OR = 27; 95% CI, 1.6-463.5), and herpetic lesions (OR = 27; 95% CI, 1.6-463.5). Prior cyclosporine use was associated with gingival hyperplasia (P =.0001). No other predictors for oral manifestations or treatment outcomes were found.


CONCLUSIONS
Oral soft tissue changes and infections were more common in patients with AA. Prior cyclosporine use was predictive of the presence of gingival hyperplasia.
Brennan
M T
MT
Clinical Research Core, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Md, USA. Mike.Brennan@carolinashealthcare.org
Sankar
V
V
Baccaglini
L
L
Pillemer
S R
SR
Kingman
A
A
Nunez
O
O
Young
N S
NS
Atkinson
J C
JC
D000328:Adult; D000704:Analysis of Variance; D000741:Anemia, Aplastic / Q000150:complications* / Q000188:drug therapy; D016001:Confidence Intervals; D016572:Cyclosporine / Q000009:adverse effects; D004245:DMF Index; D017742:Dental Care for Chronically Ill; D005260:Female; D005500:Follow-Up Studies; D005884:Gingival Hemorrhage / Q000209:etiology; D005885:Gingival Hyperplasia / Q000139:chemically induced / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016015:Logistic Models; D008297:Male; D009059:Mouth Diseases / Q000209:etiology*; D016017:Odds Ratio; D019226:Oral Ulcer / Q000209:etiology / Q000821:virology; D010510:Periodontal Diseases / Q000209:etiology; D011693:Purpura / Q000209:etiology; D012307:Risk Factors; D013283:Stomatitis, Herpetic / Q000209:etiology; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D016572:Cyclosporine